Summary & Overview
HCPCS J9354: Injection of ado-trastuzumab emtansine, 1 mg
HCPCS Level II code J9354 denotes a per-milligram billing unit for ado-trastuzumab emtansine (T-DM1), an antibody–drug conjugate used in HER2-positive oncology care. As a drug-specific HCPCS code, J9354 is central to hospital outpatient and physician-administered chemotherapy billing and influences drug cost reporting, reimbursement negotiation, and patient cost-sharing nationally. This code matters because biologic oncology agents represent a large and growing share of oncology pharmacy spend and have significant implications for site-of-service cost differentials and payer policy.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what J9354 represents clinically and operationally, common sites of service for administration, and the payer landscape covered. The publication summarizes billing benchmarks and reimbursement patterns where available, highlights relevant policy considerations for payer coverage and site-of-service impacts, and provides clinical context about the drug’s role in HER2-directed therapy. Data not available in the input will be noted as such in applicable sections.
Billing Code Overview
HCPCS Level II code J9354 represents an injection of ado-trastuzumab emtansine, 1 mg. This code describes the drug product used for targeted oncologic therapy for patients with HER2-positive cancers and is billed per milligram of the administered agent.
Service Type: Drug administration (oncology infusion)
Typical Site of Service: Hospital outpatient infusion center, physician office infusion suite, or ambulatory infusion clinic
Clinical & Coding Specifications
Clinical Context
A typical patient is a 55–70-year-old female with HER2-positive, metastatic or unresectable locally advanced breast cancer who presents to the outpatient oncology infusion suite for intravenous administration of ado-trastuzumab emtansine. The clinical workflow begins with a physician or advanced practice provider visit to confirm indication, review prior therapies (for example, progression after trastuzumab and a taxane), verify HER2 status, and assess baseline labs including CBC, liver function tests, and cardiac function (echocardiogram or MUGA). On the day of service the infusion nurse confirms identity, reviews allergies, obtains vital signs, establishes IV access, prepares the calculated dose of J9354 (ado-trastuzumab emtansine) based on body weight, and administers per institutional protocol with premedication if clinically indicated. The patient is monitored during and after infusion for infusion-related reactions, hepatic toxicity, thrombocytopenia, and signs of cardiotoxicity. Documentation includes indication, lot numbers, amount administered in milligrams, start and stop times, any modifier-applicable circumstances (for example, partial administration or waste), and post-infusion patient status for billing and clinical records.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/not administered to any patient | Use when part of the single-use vial contents are discarded and wastage must be reported separately. |